Myopia

Myopia-control spectacle lenses reduce short-term progression in children by about 50%, though efficacy and long-term durability vary.

Segmented refractive index modeling reduced axial length errors linked to crystalline lens variation, but clinical validation is needed.

The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.

NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.

As of July 13, 2026, a meeting date has not been set.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

The relationship between ALAN exposure and myopia was found to be non-linear.

Choosing the right patients for soft lenses, orthokeratology, and spectacle lenses has long-lasting effects on the vision health of those with myopia.

The lens is scheduled to become available in the US in fall 2026.

Researchers analyzed data from 13 randomized controlled trials involving children and adolescents with myopia.

Myopia management is rarely straightforward.

For Erin Tomiyama, OD, PhD, FAAO, managing myopia in pediatric patients involves decisions that extend well beyond updating a glasses prescription.

Jeffrey J. Walline, OD, PhD, shares practical perspectives on counseling families, selecting treatment options based on lifestyle and compliance, and more.

Mark Bullimore, PhD, MCOptom, consultant for Sydnexis, weighs in on the CRL received by the company for SYD-101.

The randomized controlled trial included 196 schoolchildren in Hong Kong aged 4 to 12 years with myopia who completed the study.

Research suggests that one drop of atropine is all it takes for beneficial effects.

A global systemic review recently found that women had less access to glasses than men in low- to middle-income regions.

Myopia management is not one-size-fits-all, writes Magdalena Stec, OD, FAAO.

All 3 concentrations evaluated in the study were associated with reduced myopia progression.

The analysis included studies 31 studies identified through Web of Science, PubMed, CNKI, and Wanfang databases through October 2025.

Maria Liu, OD, PhD, MPH, MBA, FAAO, is taking the recent decision as an opportunity to reassess the role atropine plays in myopia control.

This study sheds light on use of the 0.05% atropine, which has been reported to be effective against myopia progression in some but not all studies.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, low-atropine options are a must for eye care providers in the treatment of myopia.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.